Letter

(Not) warts and all

All data on both vaccines must be considered

BMJ 2008; 337 doi: 10.1136/bmj.a2554 (Published 19 November 2008)
Cite this as: BMJ 2008;337:a2554

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Pim Kon, medical director1
  1. 1GlaxoSmithKline UK, Uxbridge UB11 1BT
  1. pim.7.kon{at}gsk.com

    The government chose the human papillomavirus (HPV) vaccine of GlaxoSmithKline (GSK), Cervarix, after considering protection against cancer causing HPV 16 and 18, HPV 6 and 11 (which cause genital warts), and HPV strains not included in the vaccine formulation; price; and supply.1

    Its decision was based on a comprehensive review of …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular